Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
2014-004559-29Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Adalimumab with Placebo (2 arms). Primary endpoint: Percentage of Participants With Clinical Remission at 8 Weeks.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2014-004559-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004559-29.